H
Howard West
Researcher at City of Hope National Medical Center
Publications - 97
Citations - 4251
Howard West is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 24, co-authored 63 publications receiving 3670 citations. Previous affiliations of Howard West include University of California, Davis.
Papers
More filters
Journal ArticleDOI
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study
Shirish M. Gadgeel,Leena Gandhi,Gregory J. Riely,Alberto Chiappori,Howard West,Michele C. Azada,Peter N. Morcos,Ruey Min Lee,Linta Garcia,Li Yu,Frederic Boisserie,Laura Di Laurenzio,Sophie Golding,Jotaro Sato,Shumpei Yokoyama,Tomohiro Tanaka,Sai-Hong Ignatius Ou +16 more
TL;DR: Alectinib was well tolerated, with promising antitumour activity in patients with ALK-rearranged NSCLC resistant to crizotinib, including those with CNS metastases.
Journal ArticleDOI
Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study
Fred R. Hirsch,Marileila Varella-Garcia,Jason McCoy,Howard West,Ana Carolina Xavier,Paul H. Gumerlock,Paul A. Bunn,Wilbur A. Franklin,John Crowley,David R. Gandara +9 more
TL;DR: Increased EGFR gene copy number detected by FISH is associated with improved survival after gefitinib therapy in patients with advanced BAC, suggesting FISH methodology can be used to assess survival potential in patients treated with EGFR tyrosine kinase inhibitors.
Journal ArticleDOI
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Alice T. Shaw,Leena Gandhi,Shirish M. Gadgeel,Gregory J. Riely,Jeremy Cetnar,Howard West,D. Ross Camidge,Mark A. Socinski,Alberto Chiappori,Tarek Mekhail,Bo H. Chao,Hossein Borghaei,Kathryn A. Gold,Ali Zeaiter,Walter Bordogna,Bogdana Balas,Oscar Puig,Volkmar Henschel,Sai-Hong Ignatius Ou +18 more
TL;DR: Alectinib showed clinical activity and was well tolerated in patients with ALK-positive NSCLC who had progressed on crizotinib and could be a suitable treatment for patients with AlK- positive disease who have progressed oncrizotin ib.
Journal ArticleDOI
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
Dong Wan Kim,Dong Wan Kim,Marcello Tiseo,Myung-Ju Ahn,Karen L. Reckamp,Karin Holmskov Hansen,Karin Holmskov Hansen,Sang-We Kim,Rudolf M. Huber,Howard West,Harry J.M. Groen,Maximilian Hochmair,Natasha B. Leighl,Scott N. Gettinger,Corey J. Langer,Luis Paz-Ares Rodríguez,Egbert F. Smit,Edward S. Kim,William M. Reichmann,Frank G. Haluska,David Kerstein,D. Ross Camidge +21 more
TL;DR: Brigatinib yielded substantial whole-body and intracranial responses as well as robust progression-free survival; 180 mg (with lead-in) showed consistently better efficacy than 90 mg, with acceptable safety.
Journal ArticleDOI
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib
Fred R. Hirsch,Marileila Varella-Garcia,Federico Cappuzzo,Jason McCoy,Lynne T. Bemis,A. C. Xavier,Rafal Dziadziuszko,Paul H. Gumerlock,Kari Chansky,Howard West,Adi F. Gazdar,L. Crinò,David R. Gandara,Wilbur A. Franklin,Paul A. Bunn +14 more
TL;DR: Combination of EGFR FISH and IHC is effective predictor for benefit from gefitinib, and patients with double-negative results are unlikely to benefit in western NSCLC populations.